AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

- 1. (Currently Amended) A method of treating or preventing hearing loss associated with epilepsy at 4 kHz or 8 kHz in a patient, the method comprising administering to the patient a composition comprising vinpocetine, or a derivative thereof in an amount effective to antagonize inhibit alterations in the auditory brainstem response (ABR) waves, and a pharmaceutically acceptable vehicle.
- 2. (Currently Amended) The method of claim 1, comprising treating alterations of retro-cochlear origin, characterized by the inhibition of the alterations of the alteration of amplitudes and latencies of the later waves of the ABR.
- 3. (Currently Amended) The method of claim 1, comprising treating hearing loss alterations of retro-cochlear origin, characterized by an increase in the auditory threshold induced by pentylenetetrazole or 4-aminopyridine the inhibition of the alteration of latencies of later waves of the ABR.
- 4. (Currently Amended) The method of claim 1, comprising administering vinpocetine or a derivative thereof in an amount effective to inhibit the epileptic cortical activity for the ictal and post-ictal periods.
- 5. (Currently Amended) The method of claim 1, wherein <u>the</u> vinpocetine or a derivative thereof is administered orally or parenterally in a pharmaceutically acceptable vehicle.
- 6. (Currently Amended) The method of claim 2, wherein <u>the</u> vinpocetine or a derivative thereof is administered orally or parenterally in a pharmaceutically acceptable vehicle.
- 7. (Currently Amended) The method of claim 3, wherein the vinpocetine or a derivative thereof is administered orally or parenterally in a pharmaceutically acceptable vehicle.

8. (Currently Amended) The method of claim 4, wherein the vinpocetine or a derivative thereof is administered orally or parenterally in a pharmaceutically acceptable vehicle.